Small-cap stock under ₹50 jumps 7% despite weak trends on Dalal Street; here's why
60-Word AI Digest
Sudarshan Pharma shares rose 7% on Wednesday after the company migrated from BSE’s SME platform to the NSE main board. Its board is scheduled to review Q2 FY27 results and a potential fundraising proposal on October 29.
Key Takeaways
- Sudarshan Pharma shares rose 7% on Wednesday after the company migrated from BSE’s SME platform to the NSE main board.
- Its board is scheduled to review Q2 FY27 results and a potential fundraising proposal on October 29.
- Full details and original dispatch available below.
Sudarshan Pharma shares rose 7% on Wednesday after the company migrated from BSE’s SME platform to the NSE main board. Its board is scheduled to review Q2 FY27 results and a potential fundraising proposal on October 29.
Original Publisher Attribution
This summary was curated from Target price, stop-loss.